CrumplinGC. The mechanism of action of quinolones. In: PercivalA, ed. Quinolones—Their future in clinical practice. Royal Soc Med Services #104, 1986:1–14.
2.
ScavoneJM, GleckmanRA, FraserDG. Cinoxacin: Mechanisms of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy1982;2:266–271.
3.
CozzarelliNR. DNA gyrase and supercoiling of DNA. Science1980;207:953–960.
4.
GellertM, MizuuchiK, O'DeaMH, ItohT, TomizawaJ.Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA1977;74:4772–4776.
5.
SmithJT. Awakening the slumbering potential of the 4-quinolone antibacterials. Pharm J1984;233:299–305.
WolfsonJJ, HooperDC. The fluroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother1985;28:581–586.
8.
FinchRG, GabbayFJ. The 6-fluoroquinolones' in vitro activity, pharmacokinetic behaviour, and in vivo considerations. In: PercivalA, ed. Quinolones—Their future in clinical practice. Royal Soc Med Services #104, 1986:17–27.
9.
ShahPM, FrechK.Overview of clinical experience with the quinolones. In: PercivalA, ed. Quinolones—Their future in clinical practice. Royal Soc Med Services #104, 1986:29–42.
10.
WijnandsWJA. The use of enoxacin in respiratory tract infections. In: PercivalA, ed. Quinolones—Their future in clinical practice. Royal Soc Med Services #104, 1986:51–57.
11.
SegretiJ, TrenholmeGM. Antibiotics I. Chest Med1986;7:393–412.
MaesenFPV, DaviesBI, GeraedtsWH, BaurC.The use of quinolones in respiratory tract infections. Drugs1987;34(Suppl 1):74–79.
14.
SaitoA, KatsuM, SaitoA, SoejimaR.Ofloxacin in respiratory tract infection: A review of the results of clinical trials in Japan. Drugs1987;34(Suppl 1):83–89.
15.
WiseR, LeighDA, eds. Pefloxacin—A laboratory and clinical evaluation of a new quinolone. J Antimicrob Chemother1986;17(Suppl B):1–118.
16.
HolmesB, BrogdenRN, RichardsDM. Norfloxacin: A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs1985;30:482–513.
17.
JensenT, PedersenSS, NielsenCH, HoibyN, HochC.The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother1987;20:585–594.
18.
DavisRL, KoupJR, Williams-WarrenJ, . Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother1987;31:915–919.
19.
RavizzolaG, PiraliF, PaolucciA, . Reduced virulence in ciprofloxacin-resistant variants of Pseudomonas aeruginosa strains. J Antimicrob Chemother1987;20:825–829.
20.
NikiY, SoejimaR, KawaneH, SumiM, UmekiS.New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest1987;92:663–669.
21.
Norfloxacin (Noroxin). The Med Letter1987;29:25–27.
